News

David Hutton from Ophthalmology Times and Jay Duker talk about wet AMD and the burdens of treatment on patients thanks to the consistent need for follow-ups and more.

Ram Kannan, PhD, FARVO, principal investigator and adjunct professor of Ophthalmology at David Geffen School of Medicine, UCLA, Doheny Eye Institute, made a pair of presentations at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans. He offers some of the highlights in a conversation with Ophthalmology Times.

Vitrectomy, lensectomy remain the primary surgical approaches for condition.

Ophthalmology Times® talked with Carlos Ciller, PhD, the co-founder and CEO of RetinAI, about technological advances the company is making to drive innovation and to accelerate drug development pipelines at this year's ARVO meeting.

Ophthalmology Times® talked with Kaustubh Ghosh, PhD, about lysyl oxidase, a recently discovered molecule that causes the blood vessels in the eye to become stiffer at this year's ARVO meeting.

These three FDA-approved ophthalmic medicines, which are now commercially available under the Harrow umbrella, were among the five products that Harrow purchased in January of 2023.

Ophthalmology Times® talked with Alfonso Sabater, MD, PhD where he discusses a patient case of his with epidermolysis bullosa at this year's ARVO meeting.

Ophthalmology Times® talked with AnnMarie Hipsley, DPT, PhD, about 3D finite element model used to understand more about the biomechanics of accommodation and dis-accommodation as it relates to functions for visual function as well as aqueous hydrodynamics at this year's ARVO meeting.

This year’s event will offer attendees both new and returning special events and features.

Ophthalmology Times® talked with Darius Moshfeghi, MD, about BUTTERFLEYE data trial results using aflibercept versus laser for the treatment of retinopathy of prematurity this year's ARVO meeting.

Efavirenz boosts cholesterol turnover in retina, brain.

Ophthalmology Times® talked with Mary Durbin, PhD, about a convolutional neural network that provides image quality assessment at this year's ARVO meeting.

Ophthalmology Times® talked with Andrew Moshfeghi, MD, MBA, about OTX-TKI in a phase 1 study looking at patients with neovascular AMD this year's ARVO meeting.

Ophthalmology Times® talked Nevin El-Nimri, MS, OD, PhD, FAAO, about the relationship between optic disc fovea distance, axial length and disc at this year's ARVO meeting.

According to the company, TSN-201 leverages AAV capsid that spreads laterally beyond subretinal injection site to facilitate safe delivery of RS1 to photoreceptors in the central retina/fovea.

Ophthalmology Times® talked with David Tabano, PhD, from Genentech about the company's first real-world data readouts for faricimab in the treatment of DME at this year's ARVO meeting.

In a question and answer session, four leading ophthalmologists share their experiences with crosslinking, offering pearls that can help peers incorporate the procedure into their practice.

Iveric Bio has promising programs including avacincaptad pegol, an important program for geographic atrophy secondary to age-related macular degeneration with a. PDUFA goal data of August 19.

Analysis signals up to 59% risk reduction in rate of vision loss compared with sham treatment at 12 months.

The UCL-Moorfields team have developed a deep learning AI model to screen for ROP, which was trained on a sample of 7,414 images of the eyes of 1,370 newborns who had been admitted to the Homerton Hospital, London, and assessed for ROP by ophthalmologists.

Glaucoma specialists nationwide reported that glaucoma-related adverse events were common after cataract surgery in children.

Managing health data as non-fungible tokens could give patients full ownership of personal health data, resulting in better patient care and research outcomes.

Ophthalmology Times® talked with Theresa Heath, MD, MBA, about Non-viral gene therapy targeting ABCA4 retinopathies at this year's ARVO meeting.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, Kiora Pharmaceuticals showed its investigational drug has the potential to restore light perception in patients who are blind or living with ultra-low vision due to retinitis pigmentosa.

Earlier this year, Théa Pharma Inc. completed the acquisition of seven branded ophthalmic products from Akorn Operating Company LLC. Those products are not impacted by Akorn’s recall of all of its drugs as it ceases all operations.

Ophthalmology Times® talked with Michael Ip, MD, about the 5 year follow-up of the original SCORE2 dataset from the NIH-sponsored clinical trial.at this year's ARVO meeting.

Photobiomodulation is an emerging treatment for dry age-related macular degeneration (AMD).

Ophthalmology Times® talked with David Brown, MD, about the PHOTON study examining the safety and efficacy of high-dose aflibercept for the treatment of diabetic macular edema (DME) at this year's ARVO meeting.